Myeloproliferative Neoplasms
No Benefit Achieved With Cytoreductive Therapy for Essential Thrombocythemia With Nonhigh Risk of Thrombosis
December 28, 2018A study with more than 2000 patient-years follow-up, researchers found cytoreductive therapy was not as effective in patients with ET who have lower risk for thrombosis.
Recommended Therapies for Polycythemia Vera Underused
December 04, 2018Phlebotomy and hydroxyurea tied to improved survival, lower risk for thrombosis in older patients.
Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
November 14, 2018Results of an open-label phase 2 study demonstrated that a dose-escalation approach can prevent worsening anemia in patients with myelofibrosis undergoing treatment with ruxolitinib.
Smoking Ups Risk of Myeloproliferative Neoplasms Overall and by Subtype
October 18, 2018In a review of data from DANHES study, researchers determined the hazard ratio for developing myeloproliferative neoplasm — any or by subtype — among smokers, occasional smokers, and ex-smokers, compared with never smokers.
Case Study: Myelofibrosis Diagnosis and Early Intervention
October 16, 2018In this Case Study, Ms Lyle discusses diagnosis and early management of myelofibrosis in a 72-year-old male patient.
Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
September 13, 2018In the EBMT ALWP study, researchers sought to determine the efficacy of myeloablative conditioning to reduce the risk for post allogeneic HCT in patients with sAML without significantly increasing non-relapse mortality.
Alternate Dosing of Ruxolitinib May Alleviate Anemia in Myelofibrosis
August 16, 2018In a phase 2 study, researchers assessed the efficacy of using a dose-escalation approach to lessen the occurrence and severity of anemia in MF treated with ruxolitinib.
Adhering to Cytoreductive Therapy Use May Improve Outcomes in Polycythemia Vera
August 15, 2018In a retrospective analysis, researchers sought to determine the use of cytoreductive therapies in patients with high-risk and low-risk PV.
A Case Study on Polycythemia Vera: Diagnosis Through CBC Management With Ruxolitinib
July 27, 2018This case follows a 35-year-old man with polycythemia vera from presentation in the ED through initiating and modifying treatment with phlebotomy and hydroxyurea, and eventually achieving optimal management of symptoms and CBC with ruxolitinib.
Effect of Myeloproliferative Neoplasm Diagnosis on Work, Employment Status
May 11, 2018Using a cross-sectional online survey, researchers sought to determine how a MPN diagnosis affects work productivity and employment for patients with polycythemia vera, essential thrombocytopenia, or myelofibrosis.
Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
March 09, 2018Researchers investigated the antileukemic activity of metformin and ruxolitinib alone and in combination in patients with myeloproliferative neoplasms.
Ruxolitinib Beneficial in Hydroxyurea Resistant/Intolerant Polycythemia Vera
December 11, 2017Data presented at ASH 2017 confirm that ruxolitinib improves hematocrit control, hematologic remission, and reduction in spleen size in some patients with polycythemia vera who fail hydroxyurea.
Ruxolitinib Not Superior to Second-line Treatments for Essential Thrombocythemia
November 03, 2017A phase 2 study compared ruxolitinib with best-available therapy as second-line treatment for patients with high-risk essential thrombocythemia or polycythemia vera who became intolerant of first-line therapy.
Complications and Management of Coagulation Disorders in Leukemia Patients
October 06, 2017[Blood and Lymphatic Cancer: Targets and Therapy] Investigators conduct 4 case studies that illustrate a range of coagulation disorders that can develop in patients with leukemia to elucidate the rationale and process of specific treatment options.
A Case of Newly Diagnosed PCV After Relapse TTP Complicated by Undiagnosed RA
October 03, 2017This case of a 63-year-old African American male with a complicated history illustrates the need for a comprehensive risk assessment of thrombosis in patients with primary polycythemia vera, especially those with concomitant conditions that predispose to thrombosis.
A Patient's Guide to Managing Symptoms of Polycythemia Vera (Fact Sheet)
September 15, 2017This fact sheet reviews common symptoms associated with polycythemia vera (PV) and how a patient may address them, along with an overview of more serious symptoms that require medical attention.
Arthritis Medication Shows Potential in the Treatment of Polycythemia Vera
August 21, 2017Methotrexate, a medication used commonly in the treatment of arthritis, shows promise as a treatment for polycythemia vera, a blood cancer classified as a myeloproliferative neoplasm.
Decitabine Improves Overall Survival, Overall Response Rate in Chronic Myelomonocytic Leukemia
August 01, 2017Patients with high-risk chronic myelomonocytic leukemia (CMML), a MDS/myeloproliferative neoplasm, may experience prolonged overall survival and increased overall response rate from treatment with decitabine.
First Case of Dermatomyositis Associated with Secondary Myelofibrosis Following Polycythemia Vera
June 30, 2017A male patient with a history of polycythemia vera that converted to myelofibrosis becomes a first known case of dermatomyositis associated with secondary myelofibrosis.
Unexplained Leukocytosis, Thrombocytosis in MPN Warrants Evaluation for CML
June 05, 2017A chart review reveals 3 cases of CML developing in patients with diagnoses of ET and PV.
Impact of ET Treatments on Secondary Malignancies Not Statistically Significant
May 26, 2017Treatments for essential thrombocythemia (ET) comprising hydroxyurea and alkylating agents did not appear to impact development of secondary malignancies in patients with ET.
Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers
May 26, 2017A lack of needed transfusion services was cited as why many hematologic oncologists are less likely to refer their patients with blood cancers to home hospice care.
JAK2 Mutation, Leukocytosis Are Predictive Factors of Thrombosis in Essential Thrombocythemia
May 10, 2017Presence of JAK2 mutation and leukocytosis are strong predictors for thromboembolic events in patients with essential thrombocythemia (ET).
Improving Outcomes with Clinical Practice Guidelines for Myeloproliferative Neoplasms
May 09, 2017NCCN released its newest Clinical Practice Guidelines in Oncology. These guidelines will assist with preventive, diagnostic, and treatment decisions for patients with myelofibrosis, as well as the other myeloproliferative neoplasms, essential thrombocythemia and PV.
New Predisposition Genes for Familial Polycythemia Vera Are Identified
May 02, 2017Predisposition genes for familial polycythemia vera were identified via exome sequencing in a Finnish family with 4 patients.
JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
April 21, 2017Myelofibrosis, extensive splenomegaly, and symptomatic burden are significantly improved for patients with MPN by JAK1 and JAK2 inhibition; however, some major needs in this patient group are still largely unmet.
Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
April 20, 2017This fact sheet examines the various kinds of chronic myeloproliferative neoplasms, and the tests utilized to detect and diagnose them.
Importance of GM-CSF Autoantibodies in Pulmonary Alveolar Proteinosis With MPN
April 20, 2017A case of simultaneous PAP and MPN diagnoses demonstrate the importance of evaluating for GM-CSF autoantibodies to distinguish autoimmune and secondary forms of PAP.
Genetic Underpinnings of Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms May Provide New Insights
April 19, 2017Risk factors for splanchnic vein thrombosis in patients with myeloproliferative neoplasms are multifactorial, involving both environmental and host genetic factors.
Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
February 24, 2017Simtuzumab is well-tolerated but has inconsistent clinical benefit for patients with myelofibrosis.
Sign Up for Free e-newsletters
ONA Articles
- Cancer Treatment and Research: What Lies Ahead in 2019
- Helping Patients Face the Challenge of Eating Healthy During Cancer Treatment
- Regular Physical Activity — Even Initiated Postdiagnosis — Improves Survival for Cancer Patients
- Continuous Therapy May Be Beneficial in Patients With Newly Diagnosed Multiple Myeloma
- Gastrointestinal Perforation Complicates Management of Mantle Cell Lymphoma
- Brain Exercise Program Eases Chemobrain in Breast Cancer Survivors
- Hormone Therapy for Breast Cancer (Fact Sheet)
- Counseling on the Dangers of Vaping
- Radical Prostatectomy vs Active Surveillance: Results of Nearly 3 Decades of Follow-up
- Potential of Fecal Microbiota Transplantation in Managing Immunotherapy-Associated Colitis
- Ixazomib Maintenance After ASCT Improves Progression-Free, Overall Survival in Multiple Myeloma
- Evolutionary Role of Chemotherapy in Advanced Nasopharyngeal Carcinoma: A Literature-based Network Meta-analysis
- Helping Patients Face the Challenge of Eating Healthy During Cancer Treatment
- Gastrointestinal Perforation Complicates Management of Mantle Cell Lymphoma
- Modernizing Eligibility Criteria Could Increase Access to, Participation in Clinical Trials
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |